ACADIA PHARMACEUTICALS INC.

acadia-pharmaceuticals-inc-logo

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neuro... logical and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.

#SimilarOrganizations #People #Financial #Event #Website #More

ACADIA PHARMACEUTICALS INC.

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
1993-07-16

Address:
San Diego, California, United States

Country:
United States

Website Url:
http://www.acadia-pharm.com

Total Employee:
501+

Status:
Active

Contact:
(858) 558-2871

Email Addresses:
[email protected]

Total Funding:
811.73 M USD

Technology used in webpage:
SPF Google Tag Manager Domain Not Resolving Global Site Tag Mobile Non Scaleable Content Euro IPv6 Google Maps Google Maps API Cloudflare Hosting


Similar Organizations

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.


Current Advisors List

laura-a-brege_image

Laura A. Brege Member Board of Directors @ Acadia Pharmaceuticals Inc.
Board_member
2008-06-01

not_available_image

Arvid Carlsson Scientific and Clinical Advisor @ Acadia Pharmaceuticals Inc.
Advisor

not_available_image

Paul Anderson Member of the Scientific and Clinical Advisory Board @ Acadia Pharmaceuticals Inc.
Advisor

lester-kaplan_image

Lester Kaplan Board of Directors @ Acadia Pharmaceuticals Inc.
Board_member

not_available_image

Michael T. Borer Board of Directors @ Acadia Pharmaceuticals Inc.
Board_member

herbert-y-meltzer_image

Herbert Y. Meltzer Scientific and Clinical Advisor @ Acadia Pharmaceuticals Inc.
Advisor

torsten-rasmussen_image

Torsten Rasmussen Board of Directors @ Acadia Pharmaceuticals Inc.
Board_member

not_available_image

Leslie L. Iversen Board of Directors @ Acadia Pharmaceuticals Inc.
Board_member

Current Employees Featured

elena-ridloff_image

Elena Ridloff
Elena Ridloff Executive Vice President, Chief Financial Officer @ Acadia Pharmaceuticals Inc.
Executive Vice President, Chief Financial Officer
2019-04-01

steve-davis_image

Steve Davis
Steve Davis Chief Executive Officer & Board Member @ Acadia Pharmaceuticals Inc.
Chief Executive Officer & Board Member

michael-yang_image

Michael Yang
Michael Yang EVP & Chief Commerical Officer @ Acadia Pharmaceuticals Inc.
EVP & Chief Commerical Officer
2017-03-01

spyros-papapetropoulos_image

Spyros Papapetropoulos
Spyros Papapetropoulos Chief Development Officer & Executive R&D Advisor @ Acadia Pharmaceuticals Inc.
Chief Development Officer & Executive R&D Advisor
2019-11-01

srdjan-stankovic_image

Srdjan Stankovic
Srdjan Stankovic President @ Acadia Pharmaceuticals Inc.
President
2018-11-01

not_available_image

Gudarz Davar
Gudarz Davar EVP, Head of Research & Development @ Acadia Pharmaceuticals Inc.
EVP, Head of Research & Development
2020-08-01

william-bill-m-wells_image

William (Bill) M. Wells
William (Bill) M. Wells Director @ Acadia Pharmaceuticals Inc.
Director

not_available_image

Mark R. Brann
Mark R. Brann Founder @ Acadia Pharmaceuticals Inc.
Founder

austin-d-kim_image

Austin D. Kim
Austin D. Kim Executive Vice President & General Counsel & Secretary @ Acadia Pharmaceuticals Inc.
Executive Vice President & General Counsel & Secretary
2018-01-01

mark-schneyer_image

Mark Schneyer
Mark Schneyer EVP & Chief Financial Officer @ Acadia Pharmaceuticals Inc.
EVP & Chief Financial Officer

Founder


not_available_image

Mark R. Brann

Stock Details


Company's stock symbol is NASDAQ:ACAD

Acquisitions List

Date Company Article Price
2020-08-25 CerSci Therapeutics CerSci Therapeutics acquired by Acadia Pharmaceuticals Inc. 52.5 M USD

Investors List

national-institute-of-neurological-disorders-and-stroke_image

National Institute of Neurological Disorders and Stroke

National Institute of Neurological Disorders and Stroke investment in Grant - Acadia Pharmaceuticals Inc.

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.

venrock_image

Venrock

Venrock investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.

nomura-international_image

Nomura International

Nomura International investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.

oxford-bioscience-partners_image

Oxford Bioscience Partners

Oxford Bioscience Partners investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.

oxford-bioscience-partners_image

Oxford Bioscience Partners

Oxford Bioscience Partners investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.

abn-amro_image

ABN AMRO Fund

ABN AMRO Fund investment in Series F - Acadia Pharmaceuticals Inc.

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series F - Acadia Pharmaceuticals Inc.

ld-pensions_image

LD Pensions

LD Pensions investment in Series F - Acadia Pharmaceuticals Inc.

federated-investors_image

Federated Investors

Federated Investors investment in Series F - Acadia Pharmaceuticals Inc.

Official Site Inspections

http://www.acadia-pharm.com Semrush global rank: 3.31 M Semrush visits lastest month: 4.9 K

  • Host name: 172.67.75.53
  • IP address: 172.67.75.53
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Acadia Pharmaceuticals Inc."

About Acadia Pharmaceuticals

This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from …See details»

Acadia Pharmaceuticals Canada: Breakthroughs in …

Oct 16, 2024 At Acadia Canada, we are committed to developing therapies in areas with high unmet needs, elevating life to ensure a brighter future for all. ... [email protected] Media Inquiries …See details»

Acadia Pharmaceuticals - Wikipedia

Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikr…See details»

Acadia Pharmaceuticals Inc. - Crunchbase Company …

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned …See details»

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia ...

Sep 23, 2024 Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and …See details»

Acadia Pharmaceuticals - The Org

Acadia is trailblazing breakthroughs in neuroscience to elevate life. They are at the forefront of healthcare, fighting for breakthroughs in our science, their therapies and the way we work, but …See details»

Acadia Pharmaceuticals Inc. Information - RocketReach

Acadia strongly recommends individuals, who receive email solicitations, to carefully verify the authenticity of the correspondence before responding. Never provide personal information or …See details»

ACADIA Pharmaceuticals Inc. (ACAD) Company Profile & Overview …

May 27, 2004 The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was …See details»

Acadia Pharmaceuticals Inc. - LinkedIn

12830 El Camino Real Suite 400 San Diego, California 92130-3331, USSee details»

ACADIA - Overview, News & Similar companies | ZoomInfo.com

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it …See details»

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia ...

Sep 23, 2024 Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected]. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) …See details»

Acadia Pharmaceuticals Announces Exclusive License Agreement …

Nov 26, 2024 Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected]. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 media@acadia …See details»

Patient Resources - Acadia Pharmaceuticals

We are engaged with organizations supporting Acadia’s full portfolio. Below are examples of some of the organizations we work closely with: American Parkinson Disease Association …See details»

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice ...

Acadia Pharmaceuticals Inc. Stephanie Fagan (858) 212-0534 [email protected]. Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 ir@acadia …See details»

Acadia Pharmaceuticals to Participate at Upcoming Investor …

Nov 21, 2024 SAN DIEGO--(BUSINESS WIRE)--Nov. 21, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor …See details»

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia ...

Sep 23, 2024 Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 [email protected] Contacts Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani …See details»

Our History | Acadia Pharmaceuticals

Acadia initiates Phase 3 CLARITY program with pimavanserin as adjunctive treatment for major depressive disorder. ‡ Acadia presents positive top-line results from pivotal Phase 3 …See details»

Acadia Pharmaceuticals Reports Third Quarter 2024 ... - Morningstar

Nov 6, 2024 Acadia will host a conference call to discuss the third quarter 2024 results today, Wednesday, November 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be …See details»

Acadia Pharmaceuticals Announces Exclusive License Agreement …

Nov 26, 2024 Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected]. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) …See details»

Acadia Pharmaceuticals Announces Exclusive License Agreement …

SAN DIEGO, November 26, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: …See details»

linkstock.net © 2022. All rights reserved